Value‐based payment models and management of newly diagnosed prostate cancer
Cancer Medicine · 2024
DOI: 10.1002/cam4.6810 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, 2024. Verfasst von Avinash Maganty und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Health Services Research, Department of Urology, University of Michigan, Ann Arbor, Michigan, USA. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Medicare, Accountable Care Organizations. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, AHRQ HHS, Agency for Healthcare Research and Quality.
Abstract (Originalsprache)
Objective
To examine the effect of urologist participation in value‐based payment models on the initial management of men with newly diagnosed prostate cancer.
Methods
Medicare beneficiaries with prostate cancer diagnosed between 2017 and 2019, with 1 year of follow‐up, were assigned to their primary urologist, each of whom was then aligned to a value‐based payment model (the merit‐based incentive payment system [MIPS], accountable care organization [ACO] without financial risk, and ACO with risk). Multivariable mixed‐effects logistic regression was used to measure the association between payment model participation and treatment of prostate cancer. Additional models estimated the effects of payment model participation on use of treatment in men with very high risk (i.e., >75%) of non‐cancer mortality within 10 years of diagnosis (i.e., a group of men for whom treatment is generally not recommended) and price‐standardized prostate cancer spending in the 12 months after diagnosis.
Results
Treatment did not vary by payment model, both overall (MIPS—67% [95% CI 66%–68%], ACOs without risk—66% [95% CI 66%–68%], ACOs with risk—66% [95% CI 64%–68%]). Similarly, treatment did not vary among men with very high risk of non‐cancer mortality by payment model (MIPS—52% [95% CI 50%–55%], ACOs without risk—52% [95% CI 50%–55%], ACOs with risk—51% [95% CI 45%–56%]). Adjusted spending was similar across payment models (MIPS—$16,501 [95% CI $16,222–$16,780], ACOs without risk—$16,140 [95% CI $15,852–$16,429], ACOs with risk—$16,117 [95% CI $15,585–$16,649]).
Conclusions
How urologists participate in value‐based payment models is not associated with treatment, potential overtreatment, and prostate cancer spending in men with newly diagnosed disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Health Services Research, Department of Urology, University of Michigan, Ann Arbor, Michigan, USA.
- Division of Hematology/Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.
- VA Health Services Research & Development, Center for Clinical Management Research, VA Ann Arbor Healthcare System, Ann Arbor, Michigan, USA.
- Division of Nephrology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.
ORCID-Profile: Avinash Maganty
Förderung
- NCI NIH HHS
- AHRQ HHS
- Agency for Healthcare Research and Quality
- American Cancer Society
- National Cancer Institute
Zitieren
APA
Maganty, A., Kaufman, S. R., Oerline, M. K., Faraj, K. S., Caram, M. E. V., Shahinian, V. B., & Hollenbeck, B. K. (2024). Value‐based payment models and management of newly diagnosed prostate cancer. Cancer Medicine. https://doi.org/10.1002/cam4.6810
Vancouver
Maganty A, Kaufman SR, Oerline MK, Faraj KS, Caram MEV, Shahinian VB, et al. Value‐based payment models and management of newly diagnosed prostate cancer. Cancer Medicine. 2024. doi:10.1002/cam4.6810
BibTeX
@article{Maganty2024,
author = {Maganty, Avinash and Kaufman, Samuel R and Oerline, Mary K and Faraj, Kassem S and Caram, Megan E V and Shahinian, Vahakn B and Hollenbeck, Brent K},
title = {Value‐based payment models and management of newly diagnosed prostate cancer},
journal = {Cancer Medicine},
year = {2024},
doi = {10.1002/cam4.6810}
}
EUVIMED